Home › Multiple Myeloma › Ohio
Multiple Myeloma clinical trials in Ohio
46 studies for Multiple Myeloma are looking for participants at sites in Ohio.
Cities in Ohio
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06152575Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- TriHealth Cancer and Blood Institute, Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07555938A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- The Ohio State University James Cancer Hospital, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05137054A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Ohio State University, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07393282A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Ohio Health Research Institute, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07589634A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Cleveland Clinic, Cleveland
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Nov 3, 2026 · NCT07149857A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- The Christ Hospital Cancer Center, Cincinnati
- Oncology Hematology Care, Cincinnati
- University of Cincinnati, Cincinnati
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07258511Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- The Christ Hospital Cancer Center-Research, Cincinnati
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07341867A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07280013Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Cleveland Clinic Mercy Hospital, Canton
- University Hospitals Seidman Cancer Center, Cleveland
- Tri-County Hematology & Oncology Associates, Inc., Massillon
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT05974150A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06615479Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06465316Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
RecruitingObservational study
2 Months · All sexes · Updated Oct 27, 2026 · NCT00900198Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Ohio State University James Cancer Hospital, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT03761108A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- The James Cancer Hospital and Solove Research Institute At Ohio State University, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04973605A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Cleveland Clinic - Taussig Cancer Institute, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT05651932Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology, Columbus
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Oct 22, 2026 · NCT06052826A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Cleveland
- Research Site, Columbus
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Oct 21, 2026 · NCT07735637A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
- The Ohio State University /ID# 271336, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT06892522Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT07657312Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Oncology Hematology Care, Cincinnati
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT06297226A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 104, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07582432A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Cincinnati
- Research Site, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Gabrail Cancer Center, Canton
- The Christ Hospital, Cincinnati
- Dayton Physicians Network Urology, Dayton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06500884TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Cincinnati Medical Center, Cincinnati
- Kettering Health, Kettering
- West Chester Hospital, West Chester
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
- Gabrail Cancer & Research Center, Canton
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06087653Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- OhioHealth O'Bleness Hospital, Athens
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- and 15 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Canton
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05714839A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Ohio State University, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06292780Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Cincinnati
- Research Site, Cleveland
- Research Site, Columbus
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Indu and Raj Soin Medical Center, Beavercreek
- Saint Elizabeth Boardman Hospital, Boardman
- Dayton Physicians LLC-Miami Valley South, Centerville
- and 17 more
RecruitingPhase 3
All ages · All sexes · Updated Jun 10, 2026 · NCT05561387Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- The Ohio State University- The James Cancer Hospital and Solove Research Institute, Columbus
RecruitingPhase 2
Ages 19 and older · All sexes · Updated Jun 4, 2026 · NCT06974786Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 2, 2026 · NCT05145400A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
Recruiting
Ages 18 and older · All sexes · Updated May 27, 2026 · NCT07609030Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
RecruitingPhase 1
Ages 13 and older · All sexes · Updated May 5, 2026 · NCT04771572From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.